National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Rilpivirine (R), emtricitabine (F), tenofovir alafenamide (TAF) (Odefsey®)

Odefsey® (R/F/TAF) is indicated for the treatment of adults and adolescents (≥ 12 years, body weight ≥35 kg) infected with HIV 1 without known mutations associated with resistance to the NNRTI class, tenofovir or emtricitabine and with a viral load ≤ 100,000 HIV 1 RNA copies/ml.

Rapid Review

Commenced Completed Outcome
28/06/2016 11/07/2016 Reimbursement Not Recommeded

4th October 2016 The NCPE has recommended reimbursement following a re-submission of updated clinical evidence.